If none of the previous options apply, please select Rest of World below:

SELECT LOCATION

Philosophy

Performance

Insights

Documents

Events

About Us

How to Invest

Frequently Asked Questions

Email Sign Up

The future. Be there first. Invest in progress.

Today’s technologies and products are tomorrow’s museum pieces. Why invest in the status quo when you can invest in the future and help shape it? Tom Slater and Lawrence Burns explain more.

An Introduction: The Museum of Progress

https://stpukswebsharedmedia.blob.core.windows.net/mws/mglbamfx/scottish-mortgage-museum-of-progress-transcript.pdf

The Scottish Mortgage interim report is released.

Scottish Mortgage Interim Financial Report - September 2022

Latest interim report

Tom Slater and Lawrence Burns discuss portfolio performance, China, and the future outlook.

Tom Slater and Lawrence Burns discuss portfolio performance, China, and the future outlook. 

An update from the managers

Tom Slater delivers the interim management report.

Tom Slater delivers the interim management report.

Interim Management Report

Interim manager report

Click here to read the RNS announcement covering the Scottish Mortgage Interim Results

Scottish Mortgage RNS Announcement Interim Report - 30 September 2022

Latest results announcement

Scottish Mortgage holdings are not sitting back and waiting for the future, they’re shaping it.

Scottish Mortgage holdings are not sitting back and waiting for the future, they’re shaping it.

Perspectives on Progress #3

Perspectives on progress #3

Author Matthew Ball on the next-generation internet and the companies building its foundations.

Author Matthew Ball on the next-generation internet and the companies building its foundations.

Making sense of the metaverse: an interview with Matthew Ball

Making sense of the metaverse

The UK firm partnering with leading grocers to deploy its automated warehouses worldwide.

The UK firm partnering with leading grocers to deploy its automated warehouses worldwide.

Ocado’s robot retail revolution

Ocado’s robot revolution

Developing brain disease drugs is hard, but this company’s early results suggest it can succeed.

Developing brain disease drugs is hard, but this company’s early results suggest it can succeed.

Denali Therapeutics: rising to the challenge of brain disease

Source: Morningstar. Share prices are shown at closing mid price. NAVs are estimated. *Ongoing charges as at 31 March 2022. Calculated in accordance with AIC recommendations. Details of these costs can be found in the Key Information Document.

Past performance is not a guide to future performance. **Relative to FTSE All-World Index. Source: Baillie Gifford &amp; Co, FTSE.

Latest monthly factsheet

Latest annual report

Latest AGM proxy results

Legal

Terms and Conditions

Accessibility

Cookie Policy

Important Disclosures

Modern Slavery Statement

LinkedIn

YouTube

Twitter

Contact Us

Investment trusts are UK public companies and are not authorised and regulated by the Financial Conduct Authority. You may not get back the amount invested and please bear in mind that past performance is not a guide to future performance.